What Happened

TScan Therapeutics announced a strategic reorganization on September 2, 2026, laying off 75% of its workforce. This move includes pausing its heme malignancies program and prioritizing its in vivo solid tumor program. The company is also seeking strategic partnerships for its heme and autoimmune programs.

Who Is Affected

The layoffs affect 96 employees, including Chief Financial Officer Jason Amello and Chief Medical Officer Chrystal Louis. This is the second significant workforce reduction in less than a year, following a 30% layoff in November 2025.

Market Impact

• TScan is eliminating its internal manufacturing organization.
• The company is significantly reducing its research footprint.
• This reorganization extends TScan's cash runway into the second half of 2027.

What to Watch

Monitor TScan's progress in securing strategic partnerships for its heme and autoimmune programs. Additionally, watch for any further restructuring or layoffs as the company refocuses its pipeline.

Related coverage

• Takeda Pharmaceutical to lay off 247 Massachusetts employees starting July
• Genentech R&D layoffs impact top executive with nearly 30 years tenure